Management of Elevated Cholesterol in the primary prevention Group of Adult Japanese (MEGA) Study assists the view that a fasting plasma glucose level ≥100 mg/dL increases cardiovascular risk.
Aims/Introduction:  To evaluate the relationship between fasting plasma glucose (FPG) level and cardiovascular disease in patients with hypercholesterolemia, and to evaluate the effect of pravastatin on risk reduction in a post-hoc analysis of the large-scale Management of Elevated Cholesterol in the primary prevention Group of Adult Japanese (MEGA) Study.


METHODS
A total of 7832 patients were randomized to diet alone or diet plus low-dose pravastatin (10-20 mg/day, average 8.3 mg during follow-up periods) and followed for >5 years. In this analysis, the relationship between FPG and risk of cardiovascular disease events over 5 years were studied in 6673 patients with recorded baseline FPG levels by using the multivariable Cox proportional hazards model with the restricted quadratic spline based on three knots for FPG quartiles.


RESULTS
The spline curve showed an obvious sharp increased risk from a FPG of ≥100 mg/dL. The spline curve in the diet plus pravastatin group was consistently lower than in the diet group, regardless of the FPG level.


CONCLUSIONS
The risk of cardiovascular disease appears to increase when FPG is ≥100 mg/dL, with a sharp increased risk found above this level in patients with hypercholesterolemia. Statin treatment seems to be beneficial to reduce cardiovascular disease risk in this population. This trial was registered with ClinicalTrials.gov (no. NCT00211705). (J Diabetes Invest, doi: 10.1111/j.2040-1124.2011.00121.x, 2011).
Jikei University School of Medicine.
Naoko
N
Tajima
Jikei University School of Medicine.
Hideaki
H
Kurata
Department of Biostatistics/Epidemiology and Preventive Health Sciences, University of Tokyo.
Yasuo
Y
Ohashi
Department of Internal Medicine, Nippon Medical School.
Kyoichi
K
Mizuno
Mitsukoshi Health and Welfare Foundation, Tokyo, Japan.
Haruo
H
Nakamura
Cardiovascular risk; Fasting plasma glucose; Randomized controlled trial